The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...
Dr. Myron Czuczman highlighted the significance of the recent U.S. Food and Drug Administration (FDA) approval of Lymphir ...
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...
A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate ...
Niigata, Japan - A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata ...
Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma. The Food and Drug Administration has approved Lymphir (denileukin ...
Lung and bronchus cancer in young females: Exploring sex disparities across diverse racial and ethnic groups in the U.S. (2000-2020). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results